研究者詳細 - 石田　悠志

論文 - 石田　悠志

分割表示 58 件中 41 - 58 件目／全件表示 >>

Wernicke's encephalopathy in a child with autism during chemotherapy for T‐cell acute leukemia 査読

Kazumasa Zensho, Hisashi Ishida, Hiroki Nagai, Hirokazu Tsukahara, Akira Shimada

Pediatrics International 60 ( 8 ) 757 - 758 2018年8月

Simultaneous detection of ABL1 mutation and IKZF1 deletion in Philadelphia chromosome-positive acute lymphoblastic leukemia using a customized target enrichment system panel 査読国際誌

M. Aoe, H. Ishida, T. Matsubara, S. Karakawa, H. Kawaguchi, K. Fujiwara, K. Kanamitsu, K. Washio, K. Okada, M. Shibakura, A. Shimada

International Journal of Laboratory Hematology 40 ( 4 ) 427 - 436 2018年8月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Wiley

INTRODUCTION: Recent clinical outcomes of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) vastly improved owing to tyrosine kinase inhibitor (TKI). However, the genetic status would be different in each case with ABL1 gene mutation or copy number variants (CNVs) such as IKZF1 deletion. In particular, the TKI resistant clone with ABL1 kinase mutation remains problematic. The comprehensive assessment of genetic status including mutation, insertion and deletion (indel) and CNVs is necessary. METHODS: We evaluated a next-generation sequencing (NGS)-based customized HaloPlex target enrichment system panel to simultaneously detect coding mutations, indel and CNVs. We analysed approximately 160 known genes associated with hematological disorders in 5 pediatric Ph+ALL patients. RESULTS: Mono-allelic IKZF1 deletions were found in 4 patients at diagnosis. Furthermore, the mono-allelic deletions were found in exons of RB1, EBF1, PAX5 and ETV6 genes. Bi-allelic deletions were detected in CDKN2A and CDKN2B genes in 1 patient. ABL1 mutation was also detected in 1 patient at relapse. These results were almost comparable with the results of the multiplex ligation-dependent probe amplification (MLPA) method or Sanger sequence. CONCLUSION: Next-generation sequencing-based custom HaloPlex target enrichment system panel allows us to detect the coding mutations, indel, and CNVs in pediatric Ph+ALL simultaneously, and its results seem comparable with those of other methods.

DOI： 10.1111/ijlh.12805

PubMed

researchmap

Low Incidence of Osteonecrosis in Childhood Acute Lymphoblastic Leukemia Treated With ALL-97 and ALL-02 Study of Japan Association of Childhood Leukemia Study Group 査読

Kenichi Sakamoto, Toshihiko Imamura, Kentaro Kihira, Koji Suzuki, Hisashi Ishida, Hiromi Morita, Miyako Kanno, Takeshi Mori, Hidefumi Hiramatsu, Kousaku Matsubara, Kiminori Terui, Yoshihiro Takahashi, So-ichi Suenobu, Daiichiro Hasegawa, Yoshiyuki Kosaka, Koji Kato, Akiko Moriya-Saito, Atsushi Sato, Hirohide Kawasaki, Keiko Yumura-Yagi, Junichi Hara, Hiroki Hori, Keizo Horibe

Journal of Clinical Oncology 36 ( 9 ) 900 - 907 2018年3月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：American Society of Clinical Oncology (ASCO)

Purpose

Osteonecrosis (ON) is a serious complication of the treatment of childhood acute lymphoblastic leukemia (ALL); however, data relating to ON in Asian pediatric patients with ALL are scarce. Therefore, we performed a retrospective analysis of cohorts of Japanese patients with ALL to clarify the incidence, clinical characteristics, and risk factors of ON.

Patients and Methods

The incidence and characteristics of ON were determined in patients with ALL (n = 1,662) enrolled in two studies from the Japan Association of Childhood Leukemia Study (JACLS) group (n = 635 and n = 1,027 patients treated with the ALL-97 and ALL-02 protocols, respectively).

Results

In total, 24 of 1,662 patients suffered from ON, of which 12 of 635 and 12 of 1,027 patients were treated with the ALL-97 and the ALL-02 protocol, respectively. Of the 24 patients, 23 were older than 10 years. In multivariate analysis, age (≥ 10 years) was the sole significant risk factor for ON ( P < .001). Separate evaluation of patients ≥ 10 years of age indicated a 5-year cumulative incidence of ON of 7.2% (95% CI, 4.0% to 12.6%) and 5.9% (95% CI, 3.3% to 10.4%) in the ALL-97 and the ALL-02 protocol, respectively, which was lower than reported previously, despite an administration of dexamethasone (DEX) similar to that in comparable studies; however, concomitant administration of DEX and l-asparaginase was reduced in the JACLS protocols.

Conclusion

We identified a low frequency of ON in the JACLS ALL-97 and ALL-02 studies. Although the sole risk factor for ON was age (≥ 10 years), even among high-risk patients, ON incidence was significantly lower than that reported in previous studies. These results suggest that, not only the total amount of DEX, but also how DEX and l-asparaginase are administered, which affects the clearance of DEX, may be associated with ON incidence in patients with ALL.

DOI： 10.1200/jco.2017.75.5066

Web of Science

PubMed

researchmap

腎生検にて確定診断に至った移植関連血栓性微小血管障害査読

宮本智史, 宮本智史, 木村俊介, 細谷要介, 長谷川大輔, 石田悠志, 代田惇朗, 松井俊大, 吉本優里, 平林真介, 藤丸拓也, 熊本忠史, 森慎一郎, 鈴木高祐, 真部淳

臨床血液 59 ( 4 ) 2018年1月

多発肺転移を伴う甲状腺乳頭癌の自閉症児例

尾山貴徳, 野田卓男, 谷守通, 納所洋, 谷本光隆, 岩本貴行, 元木崇之, 樋口洋介, 藤原かおり, 石田悠志, 金光喜一郎, 鷲尾佳奈, 嶋田明

日本小児血液・がん学会雑誌 54 ( 3 ) 275 - 275 2017年12月

Sorafenib treatment for papillary thyroid carcinoma with diffuse lung metastases in a child with autism spectrum disorder: a case report 査読

Yousuke Higuchi, Takayuki Motoki, Hisashi Ishida, Kiichiro Kanamitsu, Kana Washio, Takanori Oyama, Takuo Noda, Yasuko Tsurumaru, Ayumi Okada, Hirokazu Tsukahara, Akira Shimada

BMC Cancer 17 ( 1 ) 2017年11月

多彩な合併症を呈するBeckwith-Wiedemann症候群に発症した乳児肝芽腫の一例

尾山貴徳, 野田卓男, 谷守通, 納所洋, 谷本光隆, 谷和祐, 石田悠志, 岡村朋香, 藤原かおり, 金光喜一郎, 鷲尾洋介, 鷲尾佳奈, 吉本順子, 嶋田明

日本小児血液・がん学会雑誌 54 ( 4 ) 333 - 333 2017年10月

Desmoid‐type fibromatosis in a boy with Down syndrome 査読

Hisashi Ishida, Kousuke Chayama, Kiichiro Kanamitsu, Kana Washio, Takehiro Tanaka, Akira Shimada

Pediatrics International 59 ( 5 ) 624 - 626 2017年4月

担当区分：筆頭著者掲載種別：研究論文（学術雑誌）出版者・発行元：Wiley

Abstract

Patients with Down syndrome (DS) have a markedly higher incidence of childhood leukemia, but a lower incidence of most solid tumors, compared with age‐matched euploid individuals. Trisomy 21 might be protective against tumorigenesis because of several tumor suppressive mechanisms. Desmoid‐type fibromatosis (DF) is a rare monoclonal, fibroblastic proliferation characterized by a variable clinical course. In recent reports, almost all cases of DF involved genomic alterations associated with activation of the Wnt/β‐catenin pathway. Here, we report the case of a boy with DS who developed DF without activation of the Wnt/β‐catenin pathway. To the best of our knowledge, this is the first case of DS involving DF.

DOI： 10.1111/ped.13241

PubMed

researchmap

その他リンク： https://onlinelibrary.wiley.com/doi/full-xml/10.1111/ped.13241

Two Relapsed Stage III Childhood Anaplastic Large Cell Lymphoma Patients with NPM-ALK Fusion in Bone Marrow from Initial Diagnosis 査読

Kanazawa Yui, Yamashita Yuka, Fujiwara Mitsuhiro, Muraoka Michiko, Washio Kana, Kanamitsu Kiichiro, Ishida Hisashi, Nakano Takae, Yamada Miho, Horibe Keizo, Tanaka Takehiro, Yoshino Tadashi, Shimada Akira

Acta Medica Okayama 70 ( 6 ) 503 - 506 2016年12月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Okayama University Medical School

Childhood anaplastic large cell lymphoma (ALCL) accounts for approx. 10–30 of cases of non-Hodgkin lymphoma, and the ALCL99 study reported 60–75 disease-free survival; however, a relatively high relapse rate was observed (25–30 ). We report 2 patients with Stage III ALCL who relapsed 6–18 months after the end of ALCL99 chemotherapy. A retrospective molecular analysis identified the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) fusion gene in the first diagnostic bone marrow samples taken from both patients. However, antibodies against the ALK protein appeared to be relatively low in the serum of both patients (×100 and ×750). An increase in chemotherapy intensity may be beneficial if Stage III ALCL patients are shown to be NPM-ALK chimera-positive in the first diagnostic bone marrow sample.

DOI： 10.18926/AMO/54815

その他リンク： http://search.jamas.or.jp/link/ui/2017326192

MIBG陰性神経芽腫に対するFDG-PETの有用性(Value of FDG-PET for the assessment of treatment efficacy in MIBG-negative neuroblastoma patients)

尾山貴徳, 野田卓男, 谷守通, 納所洋, 谷本光隆, 藤原かおり, 石田悠志, 金光喜一郎, 鷲尾佳奈, 嶋田明

日本小児血液・がん学会雑誌 53 ( 4 ) 231 - 231 2016年11月

化学療法を行った先天性全身型黄色肉芽腫症の一例(A case of congenital systemic juvenile xanthogranuloma treated with chemotherapy)

金光喜一郎, 石田悠志, 藤原かおり, 鷲尾佳奈, 田中健大, 嶋田明

日本小児血液・がん学会雑誌 53 ( 4 ) 245 - 245 2016年11月

Relapsed infant MLL‐rearranged acute lymphoblastic leukemia with additional genetic alterations 査読

Hisashi Ishida, Kiichiro Kanamitsu, Kana Washio, Michiko Muraoka, Kanae Sakakibara, Takehiro Matsubara, Hirotaka Kanzaki, Akira Shimada

Pediatric Blood & Cancer 63 ( 11 ) 2059 - 2060 2016年6月

Adults with germline CBL mutation complicated with juvenile myelomonocytic leukemia at infancy 査読

Muraoka Michiko, Okuma Chiho, Kanamitsu Kiichiro, Ishida Hisashi, Kanazawa Yui, Washio Kana, Seki Masafumi, Kato Motohiro, Takita Junko, Sato Yusuke, Ogawa Seishi, Tsukahara Hirokazu, Oda Megumi, Shimada Akira

Journal of human genetics 61 ( 6 ) 523 - 526 2016年6月

小児最重症再生不良性貧血に対する非血縁者間臍帯血移植

木村俊介, 長谷川大輔, 松井俊大, 代田惇朗, 石田悠志, 吉本優里, 平林真介, 細谷要介, 吉原宏樹, 熊本忠史, 森愼一郎, 真部淳

日本小児血液・がん学会雑誌 53 ( 1 ) 21 - 25 2016年4月

記述言語：日本語出版者・発行元：(一社)日本小児血液・がん学会

最重症再生不良性貧血の治療として、重症感染症などにより早期の移植が必要にも関わらずHLA適合ドナーが得られない場合、非血縁者間臍帯血移植やHLA不適合血縁者間移植が選択肢となる。しかし、このような代替ドナーからの移植では、移植片対宿主病や生着不全の危険が高いことが問題である。我々は、感染を反復する最重症再生不良性貧血の2歳男児に対して、HLA5/6抗原一致非血縁者間臍帯血移植を行った。総有核細胞数とCD34陽性細胞数の豊富な臍帯血を用いるとともに、前処置に低線量放射線照射を併用した。また、移植前に鉄キレート療法を行った。移植後day 20に生着が得られ、重篤な急性移植片対宿主病は認めなかった。前処置に用いた抗胸腺グロブリンの影響も疑われるサイトメガロウイルス抗原血症が5ヵ月遷延したが、非血縁者間臍帯血移植は最重症再生不良性貧血の治療選択肢のひとつとなりうると考えられた。(著者抄録)

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2016&ichushi_jid=J06030&link_issn=&doc_id=20160829280005&doc_link_id=%2Fex9syoga%2F2016%2F005301%2F005%2F0021-0025%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fex9syoga%2F2016%2F005301%2F005%2F0021-0025%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

小児固形腫瘍におけるFDG-PET/CTの有用性の検討(Usefulness of FDG-PET/CT for pediatric solid tumor)

納所洋, 野田卓男, 尾山貴徳, 谷本光隆, 嶋田明, 鷲尾佳奈, 金光喜一郎, 石田悠志

日本小児血液・がん学会雑誌 52 ( 4 ) 336 - 336 2015年10月